Milestone Data Highlights Minimal Blood Pressure Impact of Etripamil

Event summary

  • Milestone Pharmaceuticals will present data at the 2026 American College of Cardiology (ACC.26) conference demonstrating minimal blood pressure effects from etripamil (CARDAMYST™) during Phase 3 trials for PSVT.
  • The data, presented March 29, 2026, showed a mean systolic BP change of 1.8 mmHg (SD 11.2) with a single dose and 0.0 mmHg (SD 12.0) with repeat doses.
  • Adverse events of hypotension and syncope within 24 hours were low (0.4% and 0.2%, respectively) across 1,610 patients.
  • CARDAMYST™ was FDA-approved in December 2025 as the first self-administered treatment for symptomatic PSVT.

The big picture

Milestone's CARDAMYST™ represents a shift towards patient-centric care in cardiovascular medicine, offering a self-administered option for PSVT management. The data presented aims to address concerns about potential hypotension, a common side effect of CCBs, and bolster confidence in the product's safety profile. Success hinges on demonstrating real-world efficacy and navigating regulatory hurdles in key markets.

What we're watching

Clinical Adoption
The ACC presentation and subsequent physician feedback will be critical in determining the rate of adoption of CARDAMYST™ within the cardiology community, given the novelty of a self-administered nasal spray.
Regulatory Risk
The EMA’s assessment of Milestone’s Marketing Authorization Application (MMA) for etripamil, and any potential requests for additional clinical data, will significantly impact the product’s European market potential.
Commercial Execution
Milestone’s ability to effectively educate patients and physicians on the proper use and benefits of CARDAMYST™ will be key to achieving sustainable revenue growth and justifying the company’s valuation.